 |
*Read Disclaimer Sponsored Content |
|
April 15, 2026 | Unsubscribe |
|
Hello! |
We wanted to give you a quick intraday update on our new alert, SXTP. |
Following our alert this morning, SXTP opened today at 2.19 and has already rallied to a high of 2.40, so far experiencing gains of +9%. |
SXTP is presenting another breakout opportunity – just as it has done multiple times in the past. |
Yesterday, SXTP rallied from 1.96 to a high of 2.28 – experiencing gains of +16%. |
Today's continuation higher could mark the early stages of a bigger breakout opportunity unfolding. |
SXTP's 50-day moving average sits at 2.57, roughly 17% above today's open. |
A decisive breakout and close above this level could signal a strong opportunity. |
The 200-day moving average is at 4.44, more than double (+102%) from today's open, highlighting significant longer-term potential if momentum builds. |
In addition, this morning, the company announced breaking news that could be a big growth catalyst: |
“60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website” |
“WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced ARAKODA® (tafenoquine) for malaria prevention is now available for purchase on the Runway Health website, for U.S. travelers seeking more convenient protection against malaria before visiting endemic regions.” |
|
|
As the company further explains: |
“Patients can now conveniently connect with a licensed healthcare professional on Runway Health, who will independently determine whether a prescription for ARAKODA is appropriate, and then have the malaria preventive delivered to their address pre-departure.” |
|
|
ARAKODA is an FDA-approved medication indicated for the prevention of malaria in adults aged 18 years and older. |
The therapy offers a convenient, once-weekly, broad-spectrum dosing regimen that can be used in any malaria-endemic region after an initial loading phase, providing an alternative to daily malaria prevention medications. |
Here are some of the company’s comments from this press release: |
“Availability of once-weekly ARAKODA online finally makes travel-related malaria prevention more convenient and accessible,” said Kristen Landon, chief commercial officer of 60 Degrees Pharma. “The partnership with Runway Health and access to online prescriptions streamlines a critical part of travel to malaria-endemic regions.” |
|
|
“We are focused on making travel health simple and accessible,” said Josh Rome, founder and Chief Executive Officer of Runway Health. “Adding ARAKODA to our platform gives travelers another effective malaria prevention option, particularly for those who prefer a weekly dosing regimen during their travels.” |
|
|
Importantly: |
Malaria remains a significant health risk for travelers visiting many regions of Africa, South America, Asia, and Oceania. |
“Preventive medications are a key component of travel health planning and are recommended for many destinations where malaria transmission occurs. Travelers can learn more about ARAKODA® and begin the eligibility process by visiting the Runway Health website.” |
For a sustainable breakout higher, continue to watch for SXTP to make higher lows and higher highs. |
A close near the highs could be confirmation of upward momentum. |
We are continuing to monitor SXTP and will keep you updated as this develops. |
Sources: Presentation, PR, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, Website, Chart |
|
Happy Trading! |
|
AwesomeStocks Team |
|
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. |
|
|
DISCLAIMER: |
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. |
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. |
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. |
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 4/9/26 for the distribution of this advertisement about SXTP from 60 Degrees Pharmaceuticals, Inc. dated 4/15/26. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about SXTP. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. |
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: |
www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy |
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. |
|
0 التعليقات:
إرسال تعليق